{"DataElement":{"publicId":"7781322","version":"1","preferredName":"Receive Bortezomib Therapeutic Procedure Stratification Factors Status","preferredDefinition":"A response that indicates whether or not the patient received bortezomib (a dipeptide boronic acid analogue with antineoplastic activity) was previously administered; this response will to be used as a selected pre-treatment factor by which patients are segregated to assure equal balance of these factor before randomization to the intervention arms of a clinical protocol.","longName":"7781318v1.0:7781319v1.0","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"7781318","version":"1","preferredName":"Receive Bortezomib Therapeutic Procedure Stratification Factors","preferredDefinition":"To take, accept, or get something offered._A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","longName":"7781316v1.0:5544737v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"7781316","version":"1","preferredName":"Receive Bortezomib Therapeutic Procedure","preferredDefinition":"To take, accept, or get something offered.:A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"C25639:C1851:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CB7DAEB4-3D98-2581-E053-4EBD850A66EF","latestVersionIndicator":"Yes","beginDate":"2021-09-08","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-09-08","modifiedBy":"ONEDATA","dateModified":"2021-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5544737","version":"1","preferredName":"Stratification Factors","preferredDefinition":"Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","longName":"C16153","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stratification Factors","conceptCode":"C16153","definition":"Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FD8CA83-7B2E-5DA4-E053-F662850AFE65","latestVersionIndicator":"Yes","beginDate":"2016-10-27","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2016-10-27","modifiedBy":"ONEDATA","dateModified":"2016-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CB7DAEB4-3DA6-2581-E053-4EBD850A66EF","latestVersionIndicator":"Yes","beginDate":"2021-09-08","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-09-08","modifiedBy":"GARRIDOJ","dateModified":"2022-01-10","changeDescription":"Created for EAA181  - 09/08/2021 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7781319","version":"1","preferredName":"Received Bortezomib Status","preferredDefinition":"A condition or state at a particular time.","longName":"7781319v1.0","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Never received bortezomib","valueDescription":"Never Receive Bortezomib","ValueMeaning":{"publicId":"7781320","version":"1","preferredName":"Never Receive Bortezomib","longName":"7781320","preferredDefinition":"Not ever; at no time in the past (or future).: To take, accept, or get something offered.: A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Never","conceptCode":"C70543","definition":"Not ever; at no time in the past (or future).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CB7C9C59-E3A2-2124-E053-4EBD850A82A9","latestVersionIndicator":"Yes","beginDate":"2021-09-08","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-09-08","modifiedBy":"ONEDATA","dateModified":"2021-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CB7C9C59-E3BD-2124-E053-4EBD850A82A9","beginDate":"2021-09-08","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-09-08","modifiedBy":"ONEDATA","dateModified":"2021-09-08","deletedIndicator":"No"},{"value":"Received bortezomib","valueDescription":"Receive Bortezomib","ValueMeaning":{"publicId":"7781321","version":"1","preferredName":"Receive Bortezomib","longName":"7781321","preferredDefinition":"To take, accept, or get something offered.: A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CB7C9C59-E3CA-2124-E053-4EBD850A82A9","latestVersionIndicator":"Yes","beginDate":"2021-09-08","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-09-08","modifiedBy":"ONEDATA","dateModified":"2021-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CB7C9C59-E3E5-2124-E053-4EBD850A82A9","beginDate":"2021-09-08","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-09-08","modifiedBy":"ONEDATA","dateModified":"2021-09-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CB7C9C59-E388-2124-E053-4EBD850A82A9","latestVersionIndicator":"Yes","beginDate":"2021-09-08","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-09-08","modifiedBy":"GARRIDOJ","dateModified":"2022-01-10","changeDescription":"Created for EAA181, 09/08/2021 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"6013685","version":"1","longName":"Stratification Factor","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Treatment status of bortezomi","type":"Preferred Question Text","description":"Treatment status of bortezomib prior to study entry","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CB7E0264-2D8F-67AF-E053-4EBD850A8502","latestVersionIndicator":"Yes","beginDate":"2021-09-08","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-09-08","modifiedBy":"GARRIDOJ","dateModified":"2022-01-10","changeDescription":"Created for EAA181 - 09/08/2021 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}